Bide Pharmatech (688073.SH) has repurchased a total of 1.6162 million shares with a total investment of 70.4314 million yuan.
Bide Pharmaceutical (688073.SH) announced that as of February 29, 2024, the company has passed the Shanghai Securities...
Bide Pharmatech (688073.SH) announced that as of February 29, 2024, the company has repurchased a total of 1.6162 million shares through the Shanghai Stock Exchange trading system by means of centralized bidding trading. This represents 1.7783% of the company's total share capital. The highest repurchase price was 52.99 yuan/share, the lowest price was 32.36 yuan/share, and the total amount of the repurchase transaction was 70.4314 million yuan (excluding transaction costs).
Related Articles
ANTENGENE-B (06996) founders, CEO, chairman and other management increased their holdings.
CEOVU (00798) will distribute a final dividend of HK $0.0049 per share on October 30th.
HESAI-W(02525) issued a total of 785,400 rewards.
ANTENGENE-B (06996) founders, CEO, chairman and other management increased their holdings.
CEOVU (00798) will distribute a final dividend of HK $0.0049 per share on October 30th.
HESAI-W(02525) issued a total of 785,400 rewards.
RECOMMEND
Pace Of Public Fund Issuance Slows, Hong Kong Stocks Become A Primary Focus
24/03/2026
Jensen Huang In‑Depth Interview: Token Economy Surge, AI Computing’s Share Of GDP To Multiply One Hundredfold, NVIDIA’s $10 Trillion Valuation Inevitable
24/03/2026
Are U.S.‑Iran Talks Genuine? At Minimum, Wall Street Read A Clear Signal From Trump’s Five‑Minute Rally
24/03/2026
